UPLOAD Filing
Candel Therapeutics, Inc.
Date: Aug. 20, 2025 · CIK: 0001841387 · Accession: 0000000000-25-008857
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289595
Letter
Re: Candel Therapeutics, Inc. Registration Statement on Form S-3 Filed August 14, 2025 File No. 333-289595 Dear Paul Peter Tak:
August 20, 2025
Paul Peter Tak Chief Executive Officer Candel Therapeutics, Inc. 117 Kendrick Street, Suite 450 Needham, MA 02494
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: William D. Collins, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 20, 2025 Paul Peter Tak Chief Executive Officer Candel Therapeutics, Inc. 117 Kendrick Street, Suite 450 Needham, MA 02494 Re: Candel Therapeutics, Inc. Registration Statement on Form S-3 Filed August 14, 2025 File No. 333-289595 Dear Paul Peter Tak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William D. Collins, Esq. </TEXT> </DOCUMENT>